Year-end Sale % OFF 
Abstract
Fungi are an emerging source of peptide antibiotics. With the availability of a large number of model fungal genome sequences, we can expect that more and more fungal defensin-like peptides (fDLPs) will be discovered by sequence similarity search. Here, we report a total of 69 new fDLPs encoded by 63 genes, in which a group of fDLPs derived from dermatophytes are defined as a new family (fDEF8) according to sequence and phylogenetic analyses. In the oleaginous fungus Mortierella alpine, fDLPs have undergone extensive gene expansion. Our work further enlarges the fungal defensin family and will help characterize new peptide antibiotics with therapeutic potential.
Highlights
Fungal defensin-like peptides are emerging as attractive anti-infective agents due to their therapeutic efficacy, low toxicity and high serum stability [1,2]
On the basis of a combined analyses of sequence, structural, and phylogenetic data, we has identified seven Fungal defensin-like peptides (fDLPs) families [2,3], in which three members, classified as ancient invertebrate-type defensins (AITDs) [1,2,4,5], have been structurally and functionally characterized
We found that the M. alpine B6842 genome encodes 14 fDLPs (Figure 3) but only 10 were found in M. alpine ATCC 32222
Summary
Fungal defensin-like peptides (fDLPs) are emerging as attractive anti-infective agents due to their therapeutic efficacy, low toxicity and high serum stability [1,2]. On the basis of a combined analyses of sequence, structural, and phylogenetic data, we has identified seven fDLP families [2,3], in which three members (plectasin, micasin and eurocin), classified as ancient invertebrate-type defensins (AITDs) [1,2,4,5], have been structurally and functionally characterized. These fDLPs exhibit activity against several antibiotic-resistant clinical isolates with significant therapeutic potential [1,2,5,6]. This provides an array of candidates for development of new anti-infective agents against antibiotic-resistant human pathogens
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
